Evidence map›Paper›PMID 31669059›Full record

ArticleThe Journal of investigative dermatology2020

Association between Human Leukocyte Antigen Type and Keratinocyte Carcinoma Risk in Renal Transplant Recipients.

Yuhree Kim, David Wojciechowski, Vikram Pattanayak, Hang Lee, Maryam M Asgari

Open access · greenAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yuhree KimDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
David WojciechowskiDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Vikram PattanayakDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Hang LeeMGH Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
Maryam M AsgariDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address: PORES@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · US

Funding

Patient-oriented research and mentoring program in dermatologic diseasesK24AR069760 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA · 2017 to 2025
$1.9M
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progressionR01CA231264 · NCI · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA · 2019 to 2023
$1.5M
NCI NIH HHS R01 CA231264NIAMS NIH HHS K24 AR069760
6 · The paper itself

Abstract

Keratinocyte carcinoma (KC), defined as squamous cell carcinoma and basal cell carcinoma, is the most common malignancy among white, non-Hispanic renal transplant recipients. Although recent genome-wide association studies reported that class II HLA is associated with KC risk, epidemiologic data on HLA type and KC risk in renal transplant recipients is limited. Using an institutional cohort of white, non-Hispanic renal transplant recipients transplanted between 1993 and 2017, we examined the association between pretransplant molecular HLA types and KC risk. Posttransplant KCs were captured using the International Classification of Diseases codes and validated using pathology reports. Cox proportional hazards regression models were used to estimate hazard ratios of incident KC, squamous cell carcinoma, and basal cell carcinoma, adjusting for age, male sex, history of KC, Charlson comorbidity index, HLA mismatch, transplant type, year of transplant, and the type of immunosuppression. Among 617 subjects (mean age 53 years, 67% male), 10% developed posttransplant KC. Multivariable Cox regression analyses showed HLA-DRB1∗13 was associated with KC risk (hazard ratio, 1.84; 95% confidence interval, 1.00-3.38) and squamous cell carcinoma risk (hazard ratio, 2.24; 95% confidence interval, 1.12-4.49), whereas HLA-DRB1∗14 (hazard ratio, 2.81; 95% confidence interval, 1.14-6.91) was associated with basal cell carcinoma risk. Our findings suggest that a subset of renal transplant recipients with specific HLA polymorphisms may be at increased KC risk.

Indexed as

Basal Cell CarcinomaCarcinoma, Squamous CellCohort StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHistocompatibility TestingHLA-DRB1 ChainsHumansKeratinocytesKidney TransplantationMaleMiddle AgedPolymorphism, GeneticRiskHLA-DRB1*13 antigenHLA-DRB1*14:01 antigenHLA-DRB1 Chains

Identifiers

PMID31669059
PMCPMC7720817
OpenAlexW2982026864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.